ABSTRACT
Description: Refludan is a recombinant hirudin analogue that acts as an inhibitor of thrombin. It is produced by recombinant DNA technology in Saccharomyces cereυisiae cells. The 65 amino acid peptide differs from the natural leech hirudin molecule at the N-terminal end, where an isoleucine residue replaces a leucine, and in the absence of a sulfate group on the tyrosine at position 63. Refludan is supplied in a lyophilized form (50 mg/vial) to be reconstituted before intravenous administration.
